The major factors driving the growth of Non Invasive Prenatal Testing market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, the launch of new and advanced NIPT products, and increasing maternal age (growth in the risk of chromosomal abnormalities in babies)
[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690
Report Scope and Market Segmentation:
Report Metric | Details |
Market Size Available for Years | 2017–2024 |
Base Year Considered | 2018 |
Forecast Period | 2019–2024 |
Forecast Units | Value (USD Billion) |
Segments Covered | Product and Service, Application, and Region |
Geographies Covered | North America (US and Canada), Europe (Germany, UK, France, and RoE), Asia, and the Rest of the World |
Companies Covered | Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK) |
The services segment is expected to grow at the highest CAGR during the forecast period.
On the basis of product and service, the NIPT market is segmented into products and services. The services segment is expected to grow at the highest CAGR during the forecast period. Factors such as the rising incidence of genetic disorders, increasing focus on prenatal screening, and government initiatives to provide prenatal testing services are contributing to the growth of this market.
The trisomy segment accounted for the largest share of the market
On the basis of application, the NIPT market is segmented into trisomy, microdeletion syndrome, and other applications. The trisomy segment accounted for the largest share of the non-invasive prenatal testing market. This segment is also expected to register the highest CAGR during the forecast period.
North America dominated the NIPT market
Growth in the North American market is supported by the presence of a better reimbursement structure and a favorable funding scenario for research activities, rising awareness about NIPT, and the increasing demand for the early detection of birth defects in this region.
Illumina, Inc. (US)
Illumina is one of the major players in the non-invasive prenatal testing market. The company offers a range of highly interconnected products related to sequencing, genotyping, gene expression, and molecular diagnostics. It also offers whole-genome sequencing, genotyping, NIPT, and support services which further strengthen its market position.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690
